Patents by Inventor Sarah Vakili

Sarah Vakili has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240148296
    Abstract: Systems, methods, and devices for implementing cognitive behavioral therapy to help a subject to manage a psychiatric or mental condition of the subject are provided. Interactive digital reality (DR) activities are provided through an interactive DR scene, each configured for a subject to practice a specific reframing technique. In some embodiments, a method also includes providing one or more additional psychotherapeutic or psychoeducational techniques. Through the practice of satisfying conditions associated with each interactive DR activity, the systems, methods, and devices help a subject to manage a psychiatric or mental condition of the subject, such as by getting better at recognizing and/or challenging an anxious thought as the thought occurs, and/or by reframing the anxious thought into more a different thought using the interactive DR scene.
    Type: Application
    Filed: October 13, 2023
    Publication date: May 9, 2024
    Applicants: BehaVR, LLC, Sumitomo Pharma Co., Ltd.
    Inventors: Roward Agulto, Jillian Ahrens, Eleanor Anderson, Todd Grinnell, Robert Hayes, Shannon Hooper, Katie Howard, Marc Recasens, Bayley Taple, Risa Weisberg, Sarah Zadd, Gazeleh Vakili
  • Patent number: 11846629
    Abstract: The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: December 19, 2023
    Assignee: Tulane University
    Inventors: Jay Rappaport, Sarah Vakili
  • Publication number: 20200018745
    Abstract: The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.
    Type: Application
    Filed: September 20, 2017
    Publication date: January 16, 2020
    Inventors: Jay Rappaport, Sarah Vakili